[go: up one dir, main page]

WO1996039126A3 - Ranitidine salts on magnesium trisilicate as an adsorbate - Google Patents

Ranitidine salts on magnesium trisilicate as an adsorbate Download PDF

Info

Publication number
WO1996039126A3
WO1996039126A3 PCT/US1996/008978 US9608978W WO9639126A3 WO 1996039126 A3 WO1996039126 A3 WO 1996039126A3 US 9608978 W US9608978 W US 9608978W WO 9639126 A3 WO9639126 A3 WO 9639126A3
Authority
WO
WIPO (PCT)
Prior art keywords
adsorbate
ranitidine
magnesium trisilicate
salts
ranitidine salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/008978
Other languages
French (fr)
Other versions
WO1996039126A2 (en
Inventor
Albert F Sorg
Kirti H Valia
Anthony B Eoga
John Denick Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Priority to AU63787/96A priority Critical patent/AU6378796A/en
Publication of WO1996039126A2 publication Critical patent/WO1996039126A2/en
Publication of WO1996039126A3 publication Critical patent/WO1996039126A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A ranitidine adsorbate on magnesium trisilicate for oral administration that is free from the bitter and unpleasant taste associated with ranitidine. The ranitidine in the adsorbate is present in a stable, amorphous form and is compatible with pharmaceutically acceptable excipients.
PCT/US1996/008978 1995-06-06 1996-06-05 Ranitidine salts on magnesium trisilicate as an adsorbate Ceased WO1996039126A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU63787/96A AU6378796A (en) 1995-06-06 1996-06-05 Ranitidine salts on magnesium trisilicate as an adsorbate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46821695A 1995-06-06 1995-06-06
US08/468,216 1995-06-06

Publications (2)

Publication Number Publication Date
WO1996039126A2 WO1996039126A2 (en) 1996-12-12
WO1996039126A3 true WO1996039126A3 (en) 1997-01-30

Family

ID=23858888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/008978 Ceased WO1996039126A2 (en) 1995-06-06 1996-06-05 Ranitidine salts on magnesium trisilicate as an adsorbate

Country Status (2)

Country Link
AU (1) AU6378796A (en)
WO (1) WO1996039126A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067116B1 (en) * 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
SK15742003A3 (en) 2001-06-22 2005-01-03 Pfizer Products Inc. Pharmaceutical composition of adsorbates of amorphous drug
WO2005023225A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Cilostazol adsorbate
EP2072042A1 (en) * 2007-12-21 2009-06-24 Lek Pharmaceuticals D.D. Active pharmaceutical ingredient on solid support, amorphous and with improved solubility
EP2238979A1 (en) * 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Active pharmaceutical ingredient adsorbed on solid support

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2636532A1 (en) * 1988-09-20 1990-03-23 Glaxo Group Ltd PHARMACEUTICAL COMPOSITIONS
EP0526862A1 (en) * 1991-08-06 1993-02-10 VECTORPHARMA INTERNATIONAL S.p.A. Solid pharmaceutical compositions for oral administration with prolonged gastric residence

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2636532A1 (en) * 1988-09-20 1990-03-23 Glaxo Group Ltd PHARMACEUTICAL COMPOSITIONS
EP0526862A1 (en) * 1991-08-06 1993-02-10 VECTORPHARMA INTERNATIONAL S.p.A. Solid pharmaceutical compositions for oral administration with prolonged gastric residence

Also Published As

Publication number Publication date
AU6378796A (en) 1996-12-24
WO1996039126A2 (en) 1996-12-12

Similar Documents

Publication Publication Date Title
USD423786S (en) Combined tooth and tongue brush with timing device
USD446959S1 (en) Side chair
USD391783S (en) Entertainment side unit
AU5391490A (en) Pharmaceutical formulation
CA2123160A1 (en) Controlled release formulation
USD314473S (en) Adjustable settee
MX9803344A (en) Stable freeze-dried pharmaceutical formulation.
USD341424S (en) Post operative bunion splint
AU7305594A (en) Physiologically active substance-prolonged releasing-type pharmaceutical preparation
EP0839526A3 (en) Solid pharmaceutical preparation with fast buccal disintegration or dissolution
CA2259148A1 (en) Solid oral dosage forms of valsartan
AU5515296A (en) Composition for oral administration
AU2003238221A1 (en) Ibuprofen suspension
AU8631891A (en) Isoxazole compound, pharmaceutically acceptable salt thereof, and medicinal use thereof
WO2000071108A3 (en) Methods for treatment of asthma using s-oxybutynin
USD451971S1 (en) Exercise device
USD341263S (en) Club chair
EP1440691A3 (en) Treatment of neurotic disorders
USD430748S (en) Chair
WO1996039126A3 (en) Ranitidine salts on magnesium trisilicate as an adsorbate
USD387165S (en) Retaining device for maintaining corrected dentition
USD377452S (en) Child's timing device for monitoring potty time
USD414401S (en) Cam tie down buckle
USD435190S (en) Insulated jug
USD450940S1 (en) Ottoman

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP MX NZ SG

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP MX NZ SG

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA